S
Shun Xu
Researcher at China Medical University (PRC)
Publications - 27
Citations - 789
Shun Xu is an academic researcher from China Medical University (PRC). The author has contributed to research in topics: Medicine & Lung cancer. The author has an hindex of 8, co-authored 15 publications receiving 427 citations.
Papers
More filters
Journal ArticleDOI
Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II-IIIA (N1-N2) EGFR-mutant NSCLC (ADJUVANT/CTONG1104): a randomised, open-label, phase 3 study.
Wen-Zhao Zhong,Qun Wang,Weimin Mao,Song-Tao Xu,Lin Wu,Yi Shen,Yongyu Liu,Chun Chen,Ying Cheng,Lin Xu,Jun Wang,Ke Fei,Xiaofei Li,Jian Li,Cheng Huang,Zhidong Liu,Shun Xu,Ke-Neng Chen,Shidong Xu,Lunxu Liu,Ping Yu,Bu-Hai Wang,H. Ma,Hong-Hong Yan,Xue-Ning Yang,Qing Zhou,Yi-Long Wu,Siyu Wang,Jian Hu,Wei Liu,Wei Li,Jianhua Shi +31 more
TL;DR: Adjuvant gefitinib led to significantly longer disease-free survival compared with that for vinorelbine plus cisplatin in patients with completely resected stage II-IIIA (N1-N2) EGFR-mutant NSCLC.
Journal ArticleDOI
Gefitinib Versus Vinorelbine Plus Cisplatin as Adjuvant Treatment for Stage II-IIIA (N1-N2) EGFR-Mutant NSCLC: Final Overall Survival Analysis of CTONG1104 Phase III Trial.
Wen-Zhao Zhong,Qun Wang,Weimin Mao,Songtao Xu,Lin Wu,Yucheng Wei,Yongyu Liu,Chun Chen,Ying Cheng,Rong Yin,Fan Yang,Shengxiang Ren,Xiaofei Li,Jian Li,Cheng Huang,Zhidong Liu,Shun Xu,Ke-Neng Chen,Shidong Xu,Lunxu Liu,Ping Yu,Bu-Hai Wang,Haitao Ma,Jin-Ji Yang,Hong-Hong Yan,Xue-Ning Yang,Si-Yang Liu,Qing Zhou,Yi-Long Wu +28 more
TL;DR: Adjuvant therapy with gefitinib in patients with early-stage NSCLC and EGFR mutation demonstrated improved DFS over standard of care chemotherapy, which was one of the longest observed in this patient group compared with historic data.
Journal ArticleDOI
The Unique Spatial-Temporal Treatment Failure Patterns of Adjuvant Gefitinib Therapy: A Post Hoc Analysis of the ADJUVANT Trial (CTONG 1104).
Song-Tao Xu,Junjie Xi,Wen-Zhao Zhong,Weimin Mao,Lin Wu,Yi Shen,Yongyu Liu,Chun Chen,Ying Cheng,Lin Xu,Jun Wang,Ke Fei,Xiaofei Li,Jian Li,Cheng Huang,Zhidong Liu,Shun Xu,Ke-Neng Chen,Shidong Xu,Lunxu Liu,Ping Yu,Bu-Hai Wang,H. Ma,Hong-Hong Yan,Xue-Ning Yang,Yongxing Zhang,Jia-Cheng Yin,Qun Wang,Yi-Long Wu +28 more
TL;DR: Adjuvant gefitinib showed advantages over VP chemotherapy in treatment failure patterns especially in extracranial metastasis and adjuvant tyrosine kinas inhibitors may be considered as a treatment option in resected stage N1–N2 EGFR‐mutant NSCLC but longer duration should be explored.
Journal ArticleDOI
CTONG1104: Adjuvant gefitinib versus chemotherapy for resected N1-N2 NSCLC with EGFR mutation—Final overall survival analysis of the randomized phase III trial 1 analysis of the randomized phase III trial.
Yi-Long Wu,Wen-Zhao Zhong,Qun Wang,Weimin Mao,Songtao Xu,Lin Wu,Chun Chen,Ying Cheng,Lin Xu,Jun Wang,Xiaofei Li,Jian Li,Cheng Huang,Zhidong Liu,Shun Xu,Jin-Ji Yang,Hong-Hong Yan,Xue-Ning Yang,Si-Yang Liu,Qing Zhou +19 more
TL;DR: AdjUVant-CTONG1104 showed adjuvant gefitinib treatment significantly improved disease-free survival (DFS) vs standard doublet chemotherapy in patients in a randomized phase 3 trial.
Journal Article
Clinical observation on vertical transmission of human papillomavirus.
TL;DR: In this article, the authors observed the possibility of maternal-fetal vertical transmission of human papillomavirus (HPV) via amniotic fluid and found that HPV deoxyribonucleic acid was found in 16 cervical secretions, 14 pharyngeal secretions and in 3 amnisiotic fluids, the positive rate was 53.3%, 46.7%, 23.1% respectively.